Creative Planning’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Creative Planning’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Hold	0	–	–	–	3878
2017 Q2	–	Hold	0	–	–	–	4889
2017 Q1	–	Hold	0	–	–	–	4963
2016 Q4	–	Hold	0	–	–	–	4898
2016 Q3	–	Sell	-13	Closed	-$6.63K	–	4778
2016 Q2	$8K	Buy	+13	New	+$7.9K	﹤0.01%	3413
2016 Q1	–	Sell	-8	Closed	-$3.98K	–	4586
2015 Q4	$5K	Buy	8 +3	+60%	+$1.7K	﹤0.01%	3713
2015 Q3	$2K	Buy	+5	New	+$2.65K	﹤0.01%	3993
2015 Q2	–	Hold	0	–	-$4K	–	3181
2015 Q1	–	Hold	0	–	–	–	3671

Other funds holding EIGR

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Creative Planning's EIGR Position: Q3 2017 in Review

Creative Planning held its Eiger BioPharmaceuticals, Inc. (EIGR) position steady in Q3 2017 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3878.

Creative Planning first reported a position in EIGR in Q3 2015 and has held it in 3 quarters since. The position peaked at $8K in Q2 2016. 33 funds tracked by Wall St. Rank hold EIGR as of Q3 2017.

Creative Planning held 0 shares of Eiger BioPharmaceuticals, Inc. worth $0 as of Q3 2017.
Creative Planning left its Eiger BioPharmaceuticals, Inc. share count unchanged in Q3 2017.
Eiger BioPharmaceuticals, Inc. made up ﹤0.01% of Creative Planning's portfolio in Q3 2017, its #3878 holding.
Creative Planning first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2015 and has held it in 3 quarters since.
Creative Planning's Eiger BioPharmaceuticals, Inc. position peaked at $8K in Q2 2016.
33 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2017.

Based on Creative Planning's 13F filing for Q3 2017, filed 17 Oct 2017.